2 completed, 2 unknown, 1 terminated, 1 withdrawn. 5 Phase 2, 2 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Unknown 2, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
| Not applicable | 1 | Terminated 1 |
Follow Stage IV Nasopharyngeal Carcinoma: new trials by email Literature Review of Stage IV Nasopharyngeal Carcinoma trials Research Report on Stage IV Nasopharyngeal Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer Durvalumab, Epacadostat - Epstein-Barr Virus Positive, Metastatic Nasopharyngeal Carcinoma | Phase 2 | Withdrawn | Alain Algazi | 2020-12-01 | 2020-10-26 | |
| PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies Fludarabine, Cyclophosphamide, Interleukin-2 - Stage IV Gastric Carcinoma, Stage IV Nasopharyngeal Carcinoma | Phase 1 / Phase 2 | Unknown | Yang Yang | 20 | 2017-04-07 | 2017-05-02 |
| Olfactory Training in Improving Sense of Smell After Radiation Therapy in Patients With Paranasal Sinus or Nasopharyngeal Cancer Physiologic Testing, Quality-of-Life Assessment, Sham Intervention - Stage 0 Nasopharyngeal Carcinoma, Stage 0 Paranasal Sinus Cancer | Not applicable | Terminated | Stanford University | 15 | 2016-12-01 | 2019-02-05 |
| Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Pembrolizumab, Vorinostat - Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma | Phase 1 / Phase 2 | Completed | University of Washington | 50 | 2015-10-08 | 2024-11-26 |
| GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma GC chemotherapy plus CIK cells (Gemcitabine, Cisplatin, Autologous CIK cells), GC chemotherapy (Gemcitabine, Cisplatin) - Stage IV Nasopharyngeal Carcinoma | Phase 2 | Unknown | Sun Yat-sen University | 40 | 2012-07-01 | 2012-08-02 |
| Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma cisplatin and 5-Fu combined with nimotuzumab - Stage IV Nasopharyngeal Carcinoma | Phase 2 | Completed | Sun Yat-sen University | 39 | 2012-05-01 | 2015-09-22 |
Nasopharyngeal Carcinoma (6) · Hodgkin Disease (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, T-Cell (1) · Nasopharyngeal Neoplasms (1) · Neoplasm Metastasis (1) · Paranasal Sinus Neoplasms (1) · Salivary Gland Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1)
Carcinoma (6) · Head and Neck Neoplasms (6) · Nasopharyngeal Diseases (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms by Site (6) · Neoplasms, Glandular and Epithelial (6) · Otorhinolaryngologic Diseases (6) · Otorhinolaryngologic Neoplasms (6) · Pharyngeal Diseases (6) · Pharyngeal Neoplasms (6) · Stomatognathic Diseases (6) · Nasopharyngeal Neoplasms (5) · Carcinoma, Squamous Cell (1) · Digestive System Diseases (1)
Cisplatin (2) · Coal Tar (1) · Cyclophosphamide (1) · Disulfides (1) · Eucalyptus Oil (1) · Gemcitabine (1) · Immunoglobulin G (1) · Interleukin-2 (1) · Therapeutics (1) · Vorinostat (1) · durvalumab (1) · epacadostat (1) · fludarabine (1) · fludarabine phosphate (1) · nimotuzumab (1)
Sun Yat-sen University (2) · Alain Algazi (1) · Stanford University (1) · University of Washington (1) · Yang Yang (1)
China (3) · United States (2)
Alain P Algazi, MD (1) · Baorui Liu, MD (1) · Chong Zhao, MD (1) · Cristina Rodriguez (1) · Jian-jun Li, M.D. (1) · Zara Patel (1)
PMID 30689735, PMID 31796519, PMID 36412064
P30CA015704 (1)